Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04562285 · ClinicalTrials.gov registry record
Sustained Immunity to COVID-19 as Measured by SARS-CoV-2 Serology Assays
A clinical trial, sponsored by Henry Ford Health System.
- Completed
- Registry status
- 829
- Enrollment target
NCT04562285 is a clinical trial that has completed, run by Henry Ford Health System. The registered enrollment target is 829 participants.
The verdict
NCT04562285 has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- 829 participants
- Enrollment target
Study Summary
The primary objective is to assess the ability of COVID-19 IgG and IgM assays to detect an immune response in COVID-19 patients in the Henry Ford Health System (HFHS), both during hospitalization and over the following 12 months.
Interventions
- DIAGNOSTIC_TEST Serologic immunoassays to SARS-CoV-2 antibodies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 829 participants |
| Start Date | 2020-06-23 |
| Est. Completion | 2024-06-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04562285
The ClinicalTrials.gov registry entry for NCT04562285 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 829 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Serologic immunoassays to SARS-CoV-2 antibodies is the first listed.
NCT04562285 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04562285 about?
NCT04562285 is a clinical study titled "Sustained Immunity to COVID-19 as Measured by SARS-CoV-2 Serology Assays". The primary objective is to assess the ability of COVID-19 IgG and IgM assays to detect an immune response in COVID-19 patients in the Henry Ford Health System (HFHS), both during hospitalization and over the following 12 months.
What is the current status of trial NCT04562285?
This trial is currently completed. The enrollment target is 829 participants. The study started on 2020-06-23. Estimated completion is 2024-06-07.
What interventions are being tested in trial NCT04562285?
The interventions under investigation include: Serologic immunoassays to SARS-CoV-2 antibodies (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04562285?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.